Who in the David Granger administration recommended Larry Singh of Linden Holding for the controversial pharmaceutical bond contract or entertained his interest in such an arrangement?
The answer to this question, observers say, would reveal much about the nature of the deal and whether it could withstand scrutiny.
However, despite Cabinet’s establishing of a sub-committee to investigate the contract and its production of a report, no light has been shed on how Singh could be sole-sourced for such a contract when he had not been in this business and had no appropriate building ready to begin accepting drugs for storage. His being favoured with the contract under these circumstances would raise questions about the rectitude of the government’s decision to go to him.
